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REVIEW
Abstract: Pulmonary arterial hypertension (PAH) is a life threatening, progressive condition
which eventually leads to fatal right heart failure. Endothelin-1 (ET-1), a potent vasoconstrictor
peptide, is increased in the pulmonary arteries of patients with pulmonary hypertension.
Endothelin-1 acts through the stimulation of 2 subtypes of receptors (endothelin receptor
subtypes A [ETA] and B [ETB]). In PAH patients, ETRAs block the deleterious vasoconstrictor
effects of ET-1, and ETRA treatment in PAH patients has been shown to be safe and efficacious.
Sitaxsentan is an orally active, highly ETA selective ETRA that, in clinical trials, has
demonstrated improvements in exercise capacity, functional class and hemodynamics in PAH
patients. Sitaxsentan has been shown to be safe, well tolerated, and associated with a lower
incidence of liver toxicity than other approved ETRAs.
Keywords: endothelin receptor antagonist, endothelin receptor inhibitor, endothelin A,
sitaxsentan, pulmonary hypertension, endothelin
Introduction Introduction Introduction Introduction Introduction
Pulmonary arterial hypertension (PAH) is a life threatening, progressive condition
characterized by vascular remodeling and vasoconstriction within small pulmonary
arteries, resulting in progressive increases in mean pulmonary arterial pressure (mPAP)
and pulmonary vascular resistance (PVR), leading to fatal right-heart failure (Rich
et al 1987; Rich 1998). While the pathogenesis of idiopathic pulmonary arterial
hypertension (IPAH) is not fully understood, there is a decreased production of
mediators with anti-remodeling, platelet disaggregating, and vasodilator properties,
including prostacyclin and nitric oxide. Additionally, there is an excess production
of mediators with profibrotic and/or prothrombotic effects, smooth muscle cell
mitogenic, and vasoconstrictor properties, such as angiotensin II, endothelin-1 (ET-
1), serotonin, and thromboxane A2. These are believed to facilitate narrowing of the
pulmonary vascular lumen and to increase vascular resistance as the result of
vasoconstriction, vascular wall remodeling, and thrombosis in situ (Barst 2001).
Endothelin-1, a potent vasoconstrictor peptide, is increased in the pulmonary
arteries of patients with pulmonary hypertension(Giaid et al 1993); endothelin levels
are also increased and correlate with the severity of disease in adults with idiopathic
primary pulmonary arterial hypertension (IPAH) (Rubens et al 2001). A strong
correlation was found between increased plasma concentrations of ET-1 and increased
pulmonary vascular resistance, as well as increased mean pulmonary arterial pressure,
in a small cohort of subjects with primary pulmonary hypertension (PPH). In addition,
a decreased 6-minute walk distance (6MWD) was also observed (Rubens et al 2001).
Two distinct endothelin (ET) receptor isoforms have been identified; Type A (ETA)
and Type B (ETB) (Benigni and Remuzzi 1999). The known pathobiologic effects of
ET-1 are believed to be principally mediated through the ETA receptor, which is
found primarily on vascular smooth muscle cells and cardiac myocytes. Activation
of ETA receptors facilitates sustained vasoconstriction of vascular smooth muscle,
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stimulation of cell proliferation or hypertrophy of vascular
smooth muscle cells of myocardium. In contrast, ETB
receptors are found primarily on endothelial cells, kidney,
and central nervous tissue and may be involved in the
clearance of ET-1, particularly in the vascular beds of the
lung and kidney. Endothelial ETB receptors facilitate
vasodilation due to the release of smooth muscle relaxants
such as nitric oxide and prostacyclin. A recently published
study of patients with PAH demonstrated that the elevated
levels of ET-1 are predominantly due to excess synthesis,
not decreased clearance, and that the clearance function of
the ETB receptor is largely maintained (Langleben et al
2006). This may ultimately play a role in the relative
effectiveness of selective or nonselective agents.
Pulmonary hypertension was a consistently fatal
condition with no effective medical treatment options before
1996; however, the past decade has witnessed an upsurge
in the development of novel therapeutic agents for PAH.
There are several approved agents for PAH including
endothelin receptor antagonists that have improved the
outlook dramatically. Treatment of PAH with endothelin
receptor antagonists has been shown to be safe and
efficacious.
Endothelin antagonists are often identified as being
“selective” (usually for the ETA type receptor) or “non-
selective” (binding to either ETA or ETB receptors with
similar affinity). A compound is considered selective if its
selectivity is greater than 100-fold for the ETA receptor
subtype (Davenport and Battistini 2002). Antagonizing the
ETA receptors, in theory, should prevent the deleterious
effects mediated by the ETA receptors and allow for the
favorable effects of ETB receptors.
Sitaxsentan is a once daily, oral, highly selective
(Davenport and Battistini 2002) ETA receptor antagonist that
has a long duration of action and high specificity for ETA
receptors (Wu et al 1999; Wu et al 1997; Tilton et al 2000).
Sitaxsentan is approximately 6500-fold more selective as
an antagonist for ETA compared with ETB receptors (Wu et
al 1997), Selective ETA receptor antagonism may be
advantageous to block the harmful vasoconstrictor effects
of ET-1 on the pulmonary vasculature, while maintaining
the vasodilator and clearance functions of the ETB receptor.
Sitaxsentan has been shown to improve exercise capacity
and cardiopulmonary hemodynamics in patients with PAH.
In addition, it has been shown to reverse and prevent
vascular remodeling in animal models (Barst et al 2004).
As such, sitaxsentan is being investigated as a therapy for
PAH.
In clinical trials, sitaxsentan, at a dose of 100 mg orally,
once-daily has been shown to have the greatest risk/benefit
in patients with PAH and will be the focus of this review.
Higher doses (300 mg and higher) of sitaxsentan have been
shown to cause an increased incidence of adverse events
without an improvement in efficacy (Barst et al 2004).
Similarly, lower doses (50 mg) have been shown to have
limited efficacy with no safety benefit (Barst et al 2006).
Sitaxsentan sodium in PAH Sitaxsentan sodium in PAH Sitaxsentan sodium in PAH Sitaxsentan sodium in PAH Sitaxsentan sodium in PAH
STRIDE-1
Sitaxsentan To Relieve Impaired Exercise (STRIDE)-1
(Barst et al 2004) was a randomized, double-blind, placebo-
controlled 12-week trial that enrolled 178 patients with
NYHA functional class II-IV PAH at 23 centers in the United
States and Canada. These included patients with idiopathic
PAH (IPAH), PAH associated with connective tissue disease
(PAH-CTD), and patients with PAH associated with
congenital heart defects (PAH-CHD). Patients were
randomized to receive placebo, sitaxsentan 100 mg, or
sitaxsentan 300 mg orally, once daily for 12 weeks. In this
study, the primary endpoint was change in peak oxygen
consumption per unit time (VO2) at Week 12 while the
secondary endpoints included 6MWD, New York Heart
Association (NYHA) functional class, VO2 at anaerobic
threshold, ventilation per carbon dioxide production (VE/
VCO2) at anaerobic threshold, hemodynamics, quality of
life using a Short Form 36 (SF-36) questionnaire, and time
to clinical worsening. Unlike previous studies at the time,
this study included patients with less severe PAH (functional
class II) and, moreover, allowed patients to be enrolled
without regard to baseline 6MWD (79.2–657.3 m).
Treatment with sitaxsentan 100 mg resulted in
statistically significant improvements in 6MWD (35 m
placebo corrected improvement, p<0.01). NYHA functional
class also significantly improved compared with placebo
(p<0.02). With treatment, 29% of the sitaxsentan 100-mg
patients improved by at least one functional class without
any deteriorations. These functional benefits were
accompanied by significant improvements (p<0.01) in
pulmonary vascular resistance (PVR) and cardiac index (CI)
both of which are predictors of long-term outcome (Rubens
et al 2001; McLaughlin et al 2002; Sitbon et al 2002;
McLaughlin et al 2005). Clinical worsening events (defined
as death, the need for epoprostenol, atrial septostomy, or
transplantation) occurred in 3 (5%) placebo patients
compared with no events in patients receiving sitaxsentan
100 mg.Vascular Health and Risk Management 2007:3(1) 153
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While liver abnormalities (increases in liver
transaminases) have been recognized as a class effect
associated with ETRAs (Channick et al 2001; Barst et al
2002; Rubin et al 2002) the 100-mg dose was not associated
with an increased incidence of aminotransferase
abnormalities (0%) compared with 3% for placebo. Higher
doses (≥300 mg) of sitaxsentan have demonstrated increased
rates of liver aminotransferases elevations (11%) suggesting
a dose response for safety and tolerability.
The most frequently reported adverse events with
sitaxsentan treatment (and more frequent than with placebo)
were headache, dizziness, nasal congestion, nausea, and
peripheral edema. No patient discontinued prematurely from
treatment with sitaxsentan.
While the safety results were promising as well as the
improvements in 6MWD and functional class, the
discrepancy between the improvement in 6MWD and peak
VO2 during CPET was unexpected. The lack of congruence
between the tests generated considerable speculation
regarding the use of the two modalities as endpoints in future
clinical trials. Subsequently, an analysis by Oudiz et al
(2006b) determined that while intra-center correlation of
change in cardiopulmonary exercise testing (CPET) and
6MWD was fairly reliable, when conducted in a large,
multicenter clinical trial, the inter-center results were not
necessarily comparable. It was determined that there was
too much inter-center variability with regard to CPET. Thus,
in multicenter trials without CPET expertise validation at
all sites before subject enrollment, this parameter could not
be considered a reliable endpoint. The lack of prior CPET
expertise validation at all STRIDE-1 sites likely contributed
to the discord of the results and thus, CPET was not
considered an endpoint in any of the future STRIDE clinical
trials.
While the STRIDE-1 results were promising,
demonstrating improvements in 6MWD and functional
class, there were limitations to the study beyond the
unreliable endpoint of peak VO2 that may have obscured
the impact of the efficacy results. Clinical trials in PAH
traditionally limit enrolment to class III/IV patients with
idiopathic PAH or PAH-CTD, that have a baseline 6MWD
of <450 m; however, STRIDE-1, as previously stated,
included milder cases (ie, functional class II PAH patients),
included PAH-CHD patients, and lacked a customary
baseline 6MWD upper limit cut-off.
Langleben et al (2004a) performed a post-hoc
analysis of the STRIDE-1 subset of patients that would have
qualified for traditional PAH study inclusion criteria (ie,
patients with functional class III/IV PAH or PAH-CTD and
a baseline 6MWD of <450 m) to elucidate the impact the
generous STRIDE-1 inclusion criteria may have had on the
efficacy results. This post-hoc analysis compared the change
from baseline to endpoint in 6MWD, hemodynamics,
functional class and safety for the placebo and sitaxsentan
treated groups; and also contracted the difference of the
placebo and sitaxsentan treated groups to discern the
placebo-corrected treatment effect. Hence, statistically
significant changes were achieved in all parameters from
baseline (Table 1), including a 45% improvement in
functional class in sitaxsentan-treated patients (p=0.0005).
Nonetheless, these findings should be considered with
regard to the limitations of the study. This study was a post-
hoc analysis, not a prospective design, therefore the data
should be considered more cautiously than the overall study.
The results of the analysis revealed in the STRIDE-1
subset of patients that would have qualified for traditional
PAH study inclusion criteria improvement in efficacy
parameters with sitaxsentan therapy was even greater than
seen in the entire STRIDE-1 population, indicating the
liberal STRIDE-1 inclusion criteria may have diminished
the magnitude of change in efficacy parameters.
Langleben’s conclusions were supported by a subsequent
study by Frost et al (2005) that confirmed the six-minute
walk test is limited by “floor effect” and “ceiling effect”
(ie, a point at which the performance is so good or so bad
that further clinically and/or statistically significant
deterioration or improvement becomes hard to detect). Thus,
lack of a 6MWD upper limit cut-off masks the impact of
efficacy measures. In addition, the authors determined that
comparison between PAH trials requires recognition of the
impact that exercise and functional differences create and
trials that do not adjust for the effects of differing enrollment
criteria should be considered with caution.
Table 1 Table 1 Table 1 Table 1 Table 1 STRIDE-1 Change from baseline to endpoint in
efficacy parameters for traditional patient population
Parameter Parameter Parameter Parameter Parameter Placebo Placebo Placebo Placebo Placebo Sitaxsentan Sitaxsentan Sitaxsentan Sitaxsentan Sitaxsentan Treatment Treatment Treatment Treatment Treatment p value p value p value p value p value
n=23 n=23 n=23 n=23 n=23 n=47 n=47 n=47 n=47 n=47 effect effect effect effect effect
6MWD (m) −26±13 39±10 +65 p=0.002
mRAP (mmHg) 2.1±0.8 −1.2±0.5 −3.3 p<0.001
mPAP (mmHg) 0.4±1.5 −4.7±1.5 −5.1 p=0.03
CI (L/min per m2) −0.09±0.09 0.38±0.06 +0.47 p<0.001
PVR (dyn⋅s⋅cm
−5) 85±60 −274±47 −359 p<0.001
Abbreviations: Abbreviations: Abbreviations: Abbreviations: Abbreviations: CI, cardiac index; mPAP, mean pulmonary arterial pressure;
mRAP, mean right atrial pressure; 6MWD, 6-minute walk test distance;
PVR, pulmonary vascular resistance.Vascular Health and Risk Management 2007:3(1) 154
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STRIDE-1X
The STRIDE-1 extension trial (STRIDE-1X) was a blinded
(sitaxsentan 100 or 300 mg/day) extension study offered to
patients completing STRIDE-1. Patients that had received
placebo treatment during STRIDE-1 were randomized to
orally receive sitaxsentan 100 mg, or sitaxsentan 300 mg
once daily for this long-term, extension trial. In this study,
all patients treated with active study drug during STRIDE-
1 and 1X, with exposure of ≤58 weeks (mean treatment
duration of 26  weeks), demonstrated a one class
improvement in NYHA functional class in the sitaxsentan
100-mg group (n=42/79, 53%). Most of the patients
improved within the first 12 weeks of active sitaxsentan
treatment; however improvement was also noted
between Weeks 12–24 in 29% of the 100-mg sitaxsentan-
treated patients. Similarly, a small number of patients first
improved during Weeks 26–55 (Horn et al 2004). While
5% of patients taking 100 mg sitaxsentan deteriorated from
baseline during the entire exposure period, none of the
patients who deteriorated had previously improved.
The group treated with 100 mg sitaxsentan demonstrated
a significantly lower incidence of elevated hepatic
transaminases (8%) than the group treated with 300 mg
sitaxsentan (19%) due to nonlinear drug kinetics. Thus, the
100-mg dosage was considered to have the best efficacy/
tolerability profile.
STRIDE-1XC
In a Canadian population, an 11-patient cohort took part in
STRIDE-1X and continued to receive open-label 100 mg
sitaxsentan. The condition of 1 patient deteriorated at
7 months of therapy. The patient was transferred to
epoprostenol therapy, and subsequently died from
progressive PAH. The remaining patients completed the
evaluation after 1 year of active therapy (mean treatment
duration of 374±20 days). Evaluated patients demonstrated
sustained significant improvements in 6MWD, functional
class, and hemodynamics, compared with baseline
(Langleben et al 2004b). 6MWD improved from 386 m at
baseline to 436 m at 1 year (p=0.04). Cardiac output
increased from 4.3 L/min to 5.4 L/min (p<0.01) and PVR
fell from 742 dyn·s·cm
−5 (9 Wood units) to 585 dyn·s·cm
−5
(7 Wood units). Mean PAP and PCWP did not significantly
change and systemic blood pressure was not affected. At
baseline one patient was functional class II and 9 patients
class III, at endpoint all 10 patients were functional class II
(p<0.01).
There were no serious adverse events during the year of
therapy in the remaining 10 patients. Likewise, there were
no occurrences of liver function abnormalities. Moreover,
there were no complications, or management difficulties,
related to the interaction between sitaxsentan and warfarin.
The most frequently reported adverse events included
headache, peripheral edema, nasal congestion, and nausea.
The occurrences of these events were consistent in rate to
those of other published reports (Barst et al 2002, 2004;
Rubin et al 2002). After 2 years of therapy, this population
continued to demonstrate sustained efficacy in 6MWD,
functional class. One patient developed multiple myeloma
during year 2, and therapy was stopped. At the end of year 2,
the remaining 9 patients were all in WHO functional class II
and 6MWD improved to 440±86 m (Langleben et al 2005).
STRIDE-2
Sitaxsentan To Relieve Impaired Exercise (STRIDE)-2
(Barst et al 2006) was a randomized, multicenter,
international, double-blind, placebo-controlled 18-
week trial, that enrolled 247 PAH patients. Two hundred
forty-five patients were randomized to receive placebo,
sitaxsentan 50 mg, sitaxsentan 100 mg, or bosentan. Patients
with WHO functional class II-IV were enrolled and included
patients with IPAH, PAH-CTD and PAH-CHD. The primary
endpoint was the change in 6MWD from baseline to
Week 18, while the secondary endpoints included change
in WHO functional class, time to clinical worsening, and
change in Borg dyspnea index score.
Subjects treated with sitaxsentan 100 mg showed
statistically significant improvement in exercise capacity
compared with placebo (31  m placebo corrected
improvement, p=0.03). The bosentan active control
treatment arm, as expected, also showed improvement over
placebo at Week 18 (29 m placebo corrected improvement,
p=0.05). Subjects in the sitaxsentan 100-mg group also had
statistically significant improvement in WHO functional
class compared with placebo (p=0.04), with 98.3% of the
subjects in the sitaxsentan 100-mg group improved or
remained unchanged. Clinical worsening was seen least
often in subjects treated with sitaxsentan 100 mg. The
difference in time to clinical worsening between the
sitaxsentan 100 mg and placebo treatment groups was not
significant.
Overall, sitaxsentan at a dose of 100 mg achieved
statistical significance on the primary efficacy parameter of
6MWD and the secondary parameter, change in WHOVascular Health and Risk Management 2007:3(1) 155
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functional class. This dose was also numerically superior in
time to clinical worsening and Borg score. The 100-mg dose
of sitaxsentan performed in a similar manner to the approved
non-selective ET receptor antagonist, bosentan, which was
included in the study to allow a qualitative comparison in a
similarly randomized population.
Treatment-related AEs were reported most frequently
in subjects randomized to open-label bosentan, followed
by subjects in the sitaxsentan 100-mg group. The majority
of AEs were mild or moderate; severe AEs were experienced
more often by subjects in the placebo group, and did not
occur in a treatment-related pattern in the other groups.
Among the treatment-related AEs, the sitaxsentan subjects
more frequently reported peripheral edema, nasal
congestion, fatigue, and insomnia than placebo subjects and
with a frequency that appeared to be dose related. Bleeding
adverse events, most commonly epistaxis, were reported in
3 placebo patients, 6 sitaxsentan 100-mg patients, and
4 bosentan patients. None of the bleeding events were
considered serious or required hospitalization, transfusion,
or treatment. The incidence of liver function abnormalities
(elevated liver aminotransferases) was 6% for placebo, 3%
for sitaxsentan 100 mg and 11% for bosentan. All events
were reversible.
Sitaxsentan inhibits warfarin metabolism via inhibition
of CYP2C9 (the principal hepatic enzyme involved in
warfarin metabolism) and bosentan induces CYP2C9
(Dingemanse and van Giersbergen 2004). Due to the effect
of sitaxsentan on inhibition of the CYP2C9, an 80%
reduction in the warfarin dose for sitaxsentan patients was
recommended at baseline for sitaxsentan-treated patients,
with adjustment made as needed to maintain international
normalized ratio (INR). Dosage adjustments occurred with
similar frequencies for the four groups. Compared with
placebo, the mean daily warfarin doses were lower for
patients treated with sitaxsentan and higher for patients
treated with bosentan. In all groups in this study, concomitant
therapy with warfarin was well tolerated, and bleeding
events were rare, non-serious, and did not require treatment.
Consistent with the STRIDE-1 study, durability of
therapy with sitaxsentan 100 mg was maintained in
STRIDE-2 with fewer premature discontinuations compared
with the placebo and bosentan groups. Only 3% of patients
in the sitaxsentan group discontinued due to adverse events
compared with 10% for placebo and 10% for bosentan.
The authors concluded “treatment with the selective ETA
receptor antagonist sitaxsentan, orally once daily at a dose
of 100 mg, improves exercise capacity and WHO functional
class in PAH patients, with a low incidence of hepatic
toxicity”.
Safety Safety Safety Safety Safety
Liver function abnormalities appear to be a class effect of
ETRA therapy (Channick et al 2001; Barst et al 2002; Rubin
et al 2002). All ETRAs have been associated, to date, with
varying rates of elevated liver aminotransferases (AST and/
or ALT >3 × ULN). In a combined analysis of 4 clinical
trials with ETRAs compared with placebo, the background
incidence of abnormal liver function in a PAH patient
population over a 12- to 28-week study period is estimated
to be 4% (Abbott et al 2006). In clinical trials, the ETRA
bosentan causes elevation of liver aminotransferases (ALT
and AST) >3 × ULN in about 11% of patients, accompanied
by elevated bilirubin in a small number of cases (Actellion
2004). The combined pivotal studies discussed here,
STRIDE-1 and -2, have demonstrated an abnormal liver
function rate of approximately 2% for sitaxsentan 100 mg
compared with a placebo rate of 5% over 12–18 weeks of
therapy. Longer studies have shown the one-year risk of
developing abnormal liver function with sitaxsentan therapy,
as measured by Kaplan-Meier analysis, is lower at 4% than
that of bosentan at 14%–15% (Girgis et al 2005; McLaughlin
et al 2005).
When prescribing any ETRA, it is important to be aware
of potential interactions with concomitant medications.
Patients with PAH frequently require anticoagulant therapy
and both sitaxsentan and bosentan affect warfarin
metabolism (Dingemanse and van Giersbergen 2004).
Bosentan induces CYP2C9, the principal hepatic enzyme
involved in the metabolism of S-warfarin, and has been
shown to reduce INR in patients receiving warfarin.
Increases in warfarin dose may be necessary to maintain a
therapeutic INR. Conversely, sitaxsentan inhibits CYP2C9
(Barst et al 2002) and can increase INR in patients being
given warfarin or similar anticoagulants. While warfarin
management is similar between bosentan, sitaxsentan, and
placebo, monitoring of coagulation status is warranted when
ETRAs are prescribed (Coyne and Dixon 2005).
A recent analysis of data from STRIDE-2 and the
STRIDE-2 extension study (STRIDE-2X) compared
bleeding rates of PAH patients treated with either sitaxsentan
or bosentan. It was concluded that bleeding rates were
similar between patients treated with bosentan and
sitaxsentan (Coyne et al 2006). This analysis also examined
the incidence of bleeding events in patients that were
anticoagulated versus those not anticoagulated. The resultsVascular Health and Risk Management 2007:3(1) 156
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revealed that bleeding rates were similar for those who were
anticoagulated and those who were not anticoagulated.
Teratogenicity appears to be a class effect of ETRAs.
Therapy with an ETRA requires a monthly pregnancy test
and the use of reliable contraception. Moreover, pregnancy
must be excluded prior to the initiation of therapy.
Conclusions Conclusions Conclusions Conclusions Conclusions
Pulmonary arterial hypertension is a progressive, life
threatening condition. Sitaxsentan may become a preferred
first-line oral endothelin receptor antagonist agent given its
once daily dosing and decreased frequency of liver function
test abnormalities. In multicenter, randomized, placebo-
controlled clinical trials in PAH patients, sitaxsentan has
been shown to improve exercise capacity (ie, 6MWD),
functional classification, and hemodynamics in PAH
subjects (Barst et al 1996, 2004; Miyamoto et al 2000;
Langleben et al 2004a; Behr et al 2005; Oudiz et al 2006a).
Sitaxsentan has also been shown to be safe and well
tolerated, and the incidence of liver function abnormalities
is low with sitaxsentan therapy. Data out to 1 and 2 years
now suggests that sitaxsentan has a durable response with a
low incidence of adverse events.
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